New Jersey

Global health R&D delivers for New Jersey

Click here to select a new state

Select a new state

US government investment in global health R&D has delivered

$1.5 billlion

to New Jersey research institutions

18,700+ new jobs

for New Jersey

New Jersey's top USG-funded global health R&D institutions

Johnson & Johnson

$726.2 million

Undisclosed NJ-based industry recipients

$274.9 million

Rutgers, The State University of New Jersey (including Rutgers Biomedical and Health Sciences and the Robert Wood Johnson Medical School)

$178.5 million

MSD (also known as Merck & Co.)

$171 million

University of Medicine and Dentistry of New Jersey (formely independent, now part of Rutgers)*

$76 million

Hackensack University Medical Center

$35.2 million

Princeton University

$16.3 million

Becton, Dickinson and Company (BD)

$15.6 million

Vaxinnate Corporation*

$4.5 million

Analytical Diagnostic Solutions Inc.

$3.9 million

Prokaryotics Inc.

$3.3 million

Allied Innovative Systems LLC

$2.9 million

Celldex Therapeutics

$2.8 million

Advanced Biodevices LLC*

$2.1 million

Soligenix Inc.

$1.5 million

PTC Therapeutics

$1.4 million

US Public Health Research Institute (formerly independent, now part of Rutgers)*

$1.3 million

Celularity

$800 thousand

Theradex Systems

$740 thousand

New Jersey Institute of Technology

$519 thousand

Drew University

$473 thousand

B&W Tek

$343 thousand

Menssana Research Inc.

$286 thousand

Nostrum Technologies

$283 thousand

Aucta Pharmaceuticals

$282 thousand

Matinas BioPharma (including Aquarius Biotechnologies)

$278 thousand

PharmaSeq Inc.*

$169 thousand

New Jersey's top areas of global health R&D by USG funding

51.7%

COVID-19

25.4%

Flioviral diseases (including Ebola, Marburg)

4.2%

HIV/AIDS

12.2%

Tuberculosis

6.4%

Other

Bacterial pneumonia & meningitis

Chikungunya

Cryptococcal meningitis

Dengue

Diarrheal diseases

Emergent non-polio enteroviruses (including EV71, D68)

Helminth infections (worms & flukes)

Kinetoplastids

Leprosy

Malaria

Multi-disease/health area R&D

Other coronaviruses (including MERS, SARS)

Reproductive health

Salmonella infections

Zika

Neglected and emerging diseases in New Jersey

Chikungunya cases

Dengue cases

121

HIV diagnoses

10654

Malaria cases

388

Mpox cases

399

Tuberculosis cases

2179

Global health R&D at work in New Jersey

Rutgers New Jersey Medical School helped develop a new rapid test for tuberculosis (TB). The test, Xpert® MTB/RIF Ultra, is a second-generation version of a test that revolutionized TB diagnosis. Like its predecessor, Ultra is fast, accurate, easy to use, and needs no extra equipment—making it particularly suitable for low-resource settings. But Ultra is better able to detect TB in children, people with HIV, and certain drug-resistant cases. Results from Ultra allow patients to start on treatment quickly and receive the appropriate therapy if their strain is drug resistant, increasing treatment success rates and reducing the spread of the world’s second deadliest infectious disease killer following COVID-19.

Footnotes

Methodology
US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
*Organization appears to be closed/out of business.
Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.